Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy.

Objective: To examine alendronates side-effect profile and effect on bone mineral density (BMD) in deflazacort-treated boys with Duchennes muscular dystrophy (DMD) and low BMD.

Design: Before-after trial.

Setting: Neuromuscular clinic at a children's hospital in Canada between 1999 and 2000.